Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3Recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 5Gastrointestinal 4Other neoplasm 3Genitourinary 3CNS 3Gynecologic 1

Conditions

Prostatic Neoplasms 2Urinary Bladder Neoplasms 1

Interventions

Docetaxel 205Prednisone 151enzalutamide 128Gemcitabine 123Radiotherapy 117Sunitinib 112Cisplatin 103Leuprolide 98pembrolizumab 96Abiraterone Acetate 94bicalutamide 87Nivolumab 85Goserelin 83Sorafenib 80Paclitaxel 79Carboplatin 77Everolimus 72Bevacizumab 71Magnetic Resonance Spectroscopy 66acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 61pazopanib 56radium Ra 223 dichloride 50Ipilimumab 49Zoledronic Acid 47Cyclophosphamide 44Radiosurgery 43Filgrastim 42abiraterone 41gallium 68 PSMA-11 40Surveys and Questionnaires 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Eflornithine × Genitourinary × Clear all
NCT00006101 2018-05-14

Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer

University of California, Irvine

Phase 2 Completed
76 enrolled 7 charts
Genitourinary

Prostatic Neoplasms

NCT00003814 2013-12-18

Eflornithine in Treating Patients With Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Completed
450 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT00086736 2013-11-19

Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy

University of Alabama at Birmingham

Phase 2 Completed
34 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡